3-Methoxy-5-{[4-(2-methoxyphenyl)piperazin-1-yl]methyl}-9H-xanthen-9-one hydrochloride

ID: ALA2401931

Chembl Id: CHEMBL2401931

PubChem CID: 71727193

Max Phase: Preclinical

Molecular Formula: C26H27ClN2O4

Molecular Weight: 430.50

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  COc1ccc2c(=O)c3cccc(CN4CCN(c5ccccc5OC)CC4)c3oc2c1.Cl

Standard InChI:  InChI=1S/C26H26N2O4.ClH/c1-30-19-10-11-20-24(16-19)32-26-18(6-5-7-21(26)25(20)29)17-27-12-14-28(15-13-27)22-8-3-4-9-23(22)31-2;/h3-11,16H,12-15,17H2,1-2H3;1H

Standard InChI Key:  SVYBDDOLOQRJPO-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 430.50

Molecular Weight (Monoisotopic): 430.1893

AlogP: 4.29

#Rotatable Bonds: 5

Polar Surface Area: 55.15

Molecular Species: NEUTRAL

HBA: 6

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 6.58

CX LogP: 4.32

CX LogD: 4.26

Aromatic Rings: 4

Heavy Atoms: 32

QED Weighted: 0.44

Np Likeness Score: -0.64

References

1. Waszkielewicz AM, Gunia A, Szkaradek N, Pytka K, Siwek A, Satała G, Bojarski AJ, Szneler E, Marona H..  (2013)  Synthesis and evaluation of pharmacological properties of some new xanthone derivatives with piperazine moiety.,  23  (15): [PMID:23787101] [10.1016/j.bmcl.2013.05.062]

2. Żelaszczyk D, Jakubczyk M, Pytka K, Rapacz A, Walczak M, Janiszewska P, Pańczyk K, Żmudzki P, Słoczyńska K, Marona H, Waszkielewicz AM..  (2019)  Design, synthesis and evaluation of activity and pharmacokinetic profile of new derivatives of xanthone and piperazine in the central nervous system.,  29  (21): [PMID:31537425] [10.1016/j.bmcl.2019.126679]

Source

Source(1):

• Scientific Literature